EGFR and cancer: In addition, some familiar metallic oxides are also established nanotheranostic platforms combined with EGFR antibody or EGFR KTI against several types of cancer (eg. ZnO NPs) (Muhammad et al., 2011; Chen et al., 2013; Cai et al., 2016; Zhang et al., 2017; Zhou et al., 2017).